The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Elizabeth A. File

Northeastern Ohio Universities College of Medicine

Rootstown

OH; Infectious Disease Service

Summa Health System

USA

[email]@summa-health.org

Name/email consistency: medium

 
 
 
 
 
 
 

Affiliations

  • Northeastern Ohio Universities College of Medicine, Rootstown, OH; Infectious Disease Service, Summa Health System, USA. 1999 - 2010
  • Infectious Disease Section, Northeastern Ohio University College of Medicine, Rootstown, USA. 2005 - 2009
  • Summa Health System, Akron Infectious Diseases Inc., OH 44304, USA. 2001 - 2005
  • Infectious Disease Service, Summa Health System, Akron, Ohio 44304, USA. 2004
  • Summa Health System, 75 Arch Street, Suite 105, Akron, USA. 2004
  • Department of Medicine, Summa Health System, Akron, USA. 2002

References

  1. Burden of community-acquired pneumonia in North American adults. File, T.M., Marrie, T.J. Postgrad. Med (2010) [Pubmed]
  2. Case studies of lower respiratory tract infections: community-acquired pneumonia. File, T.M. Am. J. Med. (2010) [Pubmed]
  3. The science of selecting antimicrobials for community-acquired pneumonia (CAP). File, T.M. J. Manag. Care. Pharm (2009) [Pubmed]
  4. Is the risk of serious infections increased in patients with RA who receive treatment with antirheumatic drugs?. File, T.M., File, E.A. Nature Clinical Practice. Rheumatology (2008) [Pubmed]
  5. What can we learn from the time course of untreated and partially treated community-onset Streptococcus pneumoniae pneumonia? A clinical perspective on superiority and noninferiority trial designs for mild community-acquired pneumonia. File, T.M., Schentag, J.J. Clin. Infect. Dis. (2008) [Pubmed]
  6. Impact of community-acquired methicillin-resistant Staphylococcus aureus in the hospital setting. File, T.M. Cleve. Clin. J. Med (2007) [Pubmed]
  7. The development of pharmacokinetically enhanced amoxicillin/clavulanate for the management of respiratory tract infections in adults. File, T.M. Int. J. Antimicrob. Agents (2007) [Pubmed]
  8. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study. File, T.M., Mandell, L.A., Tillotson, G., Kostov, K., Georgiev, O. J. Antimicrob. Chemother. (2007) [Pubmed]
  9. Clinical implications and treatment of multiresistant Streptococcus pneumoniae pneumonia. File, T.M. Clin. Microbiol. Infect. (2006) [Pubmed]
  10. Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains. File, T.M., Garau, J., Jacobs, M.R., Wynne, B., Twynholm, M., Berkowitz, E. Int. J. Antimicrob. Agents (2005) [Pubmed]
  11. Telithromycin new product overview. File, T.M. J. Allergy Clin. Immunol. (2005) [Pubmed]
  12. Community-associated methicillin-resistant Staphylococcus aureas: not only a cause of skin infections, also a new cause of pneumonia. File, T.M. Curr. Opin. Infect. Dis. (2005) [Pubmed]
  13. Severe acute respiratory syndrome: pertinent clinical characteristics and therapy. File, T.M., Tsang, K.W. Treat. Respir. Med (2005) [Pubmed]
  14. Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia. File, T.M., Garau, J., Blasi, F., Chidiac, C., Klugman, K., Lode, H., Lonks, J.R., Mandell, L., Ramirez, J., Yu, V. Chest (2004) [Pubmed]
  15. Evolution of amoxicillin/clavulanate in the treatment of adults with acute bacterial rhinosinusitis and community-acquired pneumonia in response to antimicrobial-resistance patterns. File, T.M., Benninger, M.S., Jacobs, M.R. Clin. Lab. Med. (2004) [Pubmed]
  16. New insights in the treatment by levofloxacin. File, T.M. Chemotherapy (2004) [Pubmed]
  17. Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults. File, T.M., Lode, H., Kurz, H., Kozak, R., Xie, H., Berkowitz, E. Antimicrob. Agents Chemother. (2004) [Pubmed]
  18. Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia. File, T.M. Clin. Infect. Dis. (2004) [Pubmed]
  19. Lower respiratory tract infections. File, T.M. Infect. Dis. Clin. North Am. (2004) [Pubmed]
  20. Antimicrobial therapy of community-acquired pneumonia. File, T.M., Niederman, M.S. Infect. Dis. Clin. North Am. (2004) [Pubmed]
  21. International guidelines for the treatment of community-acquired pneumonia in adults: the role of macrolides. File, T.M., Tan, J.S. Drugs (2003) [Pubmed]
  22. Necrotizing Soft Tissue Infections. File, T.M. Curr. Infect. Dis. Rep (2003) [Pubmed]
  23. Community-acquired pneumonia. File, T.M. Lancet (2003) [Pubmed]
  24. Appropriate use of antimicrobials for drug-resistant pneumonia: focus on the significance of beta-lactam-resistant Streptococcus pneumoniae. File Jr, T.M. Clin. Infect. Dis. (2002) [Pubmed]
  25. Rational use of antibiotics to treat respiratory tract infections. File, T.M., Hadley, J.A. Am. J. Manag. Care (2002) [Pubmed]
  26. Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxycillin/clavulanate. File, T.M., Jacobs, M.R., Poole, M.D., Wynne, B. Int. J. Antimicrob. Agents (2002) [Pubmed]
  27. Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin. File, T.M., Schlemmer, B., Garau, J., Cupo, M., Young, C. J. Antimicrob. Chemother. (2001) [Pubmed]
  28. Optimal treatment strategies for community-acquired pneumonia: non-responders to conventional regimens. File, T.M. Chemotherapy (2001) [Pubmed]
  29. The epidemiology of respiratory tract infections. File, T.M. Semin. Respir. Infect (2000) [Pubmed]
  30. Clinical characteristics of Chlamydia pneumoniae infection as the sole cause of community-acquired pneumonia. File, T.M., Plouffe, J.F., Breiman, R.F., Skelton, S.K. Clin. Infect. Dis. (1999) [Pubmed]
 
WikiGenes - Universities